Show notes
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S.
Transcript
Transcript not available for this episode yet.
More from The Top Line
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Aug 7, 202620 min
The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Aug 6, 202626 min
Inside Noble’s connected approach to patient support (Sponsored)
Aug 3, 202615 min
Psychedelics, peptides and GLP-1s
Jul 31, 202625 min
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min